Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Interest Expenses (2016 - 2017)

IGC Pharma (IGC) has disclosed Interest Expenses for 8 consecutive years, with $60527.0 as the latest value for Q4 2017.

  • On a quarterly basis, Interest Expenses rose 30.26% to $60527.0 in Q4 2017 year-over-year; TTM through Sep 2018 was $60527.0, a 72.4% decrease, with the full-year FY2017 number at $223464.0, up 4.46% from a year prior.
  • Interest Expenses was $60527.0 for Q4 2017 at IGC Pharma, up from $40832.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $504934.0 in Q1 2013 to a low of $34246.0 in Q1 2016.
  • A 5-year average of $83325.2 and a median of $60848.5 in 2014 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 1880.46% in 2013, then crashed 88.5% in 2014.
  • IGC Pharma's Interest Expenses stood at $52502.0 in 2013, then grew by 18.01% to $61957.0 in 2014, then dropped by 17.68% to $51000.0 in 2015, then decreased by 8.89% to $46465.0 in 2016, then skyrocketed by 30.26% to $60527.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Interest Expenses are $60527.0 (Q4 2017), $40832.0 (Q3 2017), and $44546.0 (Q2 2017).